We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Asia International ConferenceMarch 5-6, 2019
BIO IP Counsels Committee ConferenceNovember 14-16, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
Learn about the Hatch-Waxman Act and its role in balancing innovation and drug competition.
For the 340B Drug Discount Program to work properly and benefit low-income patients, reforms are needed. Our latest infographic shows why.
The Medicare Part D benefit program was created to ensure seniors have access to affordable prescription drugs.
BIO's response to "A Better Deal" proposals on drug pricing.
PDUFA provides greater consistency, certainty and predictability in the FDA's drug review programs.
Learn about how the Bayh-Dole Act benefits the U.S. economy, consumers & patients.
Importing medicines from abroad would threaten public health and do little to reduce prescription drug costs. Here's why...